Randomized controlled trial assessed digital CBT-I effectiveness in reducing insomnia severity compared to sleep hygiene education, indicating improved access is vital.
Key Points
Digital CBT-I (SleepioRx) led to significant improvement in insomnia severity index scores at 10 weeks, showing its effectiveness.
At 10 weeks, participants using SleepioRx had a mean improvement of d=0.60 on the insomnia severity index, indicating substantial clinical significance.
This decentralized randomized controlled trial enrolled a diverse group of 336 adults diagnosed with insomnia using a structured clinical interview.
Availability of FDA-cleared digital CBT-I should be expanded to improve access, emphasizing its importance in treating insomnia across patient populations.